Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
- 28 July 2013
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 16 (1), 38-47
- https://doi.org/10.1111/dom.12175
Abstract
AimsNew drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due regulatory requirements from the Food and Drug Administration. For this reason, glucagon-like peptide-1 receptor agonists (GLP-1 RA) are currently undergoing large-scale, long-term randomized trials specifically designed for cardiovascular outcomes. Aim of the present meta-analysis of randomized clinical trials is the assessment of the effects of GLP-1 RA on major cardiovascular events (MACE), mortality and cardiovascular risk factors. MethodsA meta-analysis was performed including all trials with a duration of at least 6 months, comparing a GLP-1 RA with a non-GLP-1 RA agent in type 2 diabetes. MACE and mortality were retrieved and combined to calculate Mantel-Haenzel odds ratio (MH-OR). Furthermore, data on endpoint systolic and diastolic blood pressure, total and high-density lipoprotein (HDL) cholesterol and triglyceride were collected. ResultsOf 37 selected trials, 33 reported information on MACE, and 25 reported at least one event. The difference in the incidence of MACE between GLP-1 RA and comparators did not reach statistical significance [MH-OR 0.78 (0.54-1.13), p=0.18]. GLP-1 RA were associated with a significant reduction in the incidence of MACE in comparisons with placebo and pioglitazone, with a non-significant trend towards reduction in DPP4i-controlled studies. No significant effect of GLP-1 RA was observed on mortality, although a non-significant favourable trend was observed in comparisons with placebo. ConclusionsThe present meta-analysis confirms the cardiovascular safety of GLP-1 RA, at least in the short term and in low-risk individuals. GLP-1 RA could have a beneficial effect on the incidence of MACE, at least in comparison with placebo.Keywords
This publication has 25 references indexed in Scilit:
- Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trialsDiabetes, Obesity and Metabolism, 2013
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysisBMJ Open, 2013
- Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markersVascular Health and Risk Management, 2012
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-AnalysisExperimental Diabetes Research, 2012
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsBMJ, 2011
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical TrialsExperimental Diabetes Research, 2011
- Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trialsActa Endocrinologica, 2009
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996